Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal group B vaccine - Pfizer

Next Previous
X
Search
Drug Profile

Meningococcal group B vaccine - Pfizer

Alternative Names: Bivalent recombinant LP2086; Bivalent recombinant meningococcal B vaccine - Pfizer; Bivalent rLP2086; Meningococcal B rLP2086 vaccine - Pfizer; MnB-rLP2086; PF-05212366; PF-5212366; Recombinant-LP2086; rLp-2086; rLP2086; TRUMENBA

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal group B infections

Most Recent Events

  • 29 Nov 2022 Meningococcal group B vaccine is still in phase III trials for Meningococcal group B infections (In adolescents, In adults, In children, Prevention) in Chile, Czech Republic, Finland, Poland (IM) (NCT03135834)
  • 29 Nov 2022 No development reported - Phase-II for Meningococcal group B infections (In children, In infants, Prevention) in Australia (IM) (NCT02534935)
  • 29 Nov 2022 No development reported - Phase-II for Meningococcal group B infections (In children, In infants, Prevention) in Czech Republic (IM) (NCT02534935)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top